China Medical System (CHSYF) announced that on 11 December 2025, the New Drug Application of Y-3 for Injection has been accepted by National Medical Products Administration of the People’s Republic of China. The Product is a brain cytoprotectant indicated for the treatment of acute ischemic stroke.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CHSYF:
- China Medical System’s Innovative Stroke Treatment Gains Regulatory Acceptance
- China Medical System Holdings Maintains Stable Share Capital in November 2025
- China Medical System announces NMPA acceptance of MG-K10 NDA
- China Medical System’s New Drug Application for Atopic Dermatitis Accepted in China
- China Medical System Secures Distribution Rights for Key Ophthalmic Drugs in China